Senior Medical Director, Global Medical AffairsSanofi, Cambridge, MA, USACambridge, Massachusetts, United States
OC 69.5 - Outcomes in Adult and Adolescent Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis From an Observational Study With Factor VIII Prophylaxis
Wednesday, June 28, 202311:15 – 11:30 ET
